Lutetium Lu 177 dotatate is under clinical development by Curium Midco and currently in Pre-Registration for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData, Pre-Registration drugs for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Lutetium Lu 177 dotatate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lutetium Lu 177 dotatate overview
The drug candidate is under development for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETS). It is a radioligand therapy conjugated to lutetium 177. It is administered through parenteral route and acts by targeting somatostatin receptor 2 (SSTR2).
Curium Midco overview
Curium Midco (Curium) manufactures and distributes medical radioisotopes and radiopharmaceuticals for usage in diagnostic imaging and therapeutic procedures. Curium is headquartered in Luxembourg.
For a complete picture of Lutetium Lu 177 dotatate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
